| 刘飞,吴琪,李寰舟.儿童应用磷酸奥司他韦不良反应报告 52例分析[J].安徽医药,2026,30(3):632-636. |
| 儿童应用磷酸奥司他韦不良反应报告 52例分析 |
| Analysis of 52 cases of adverse drug reactions to oseltamivir phosphate in children |
| |
| DOI：10.3969/j.issn.1009-6469.2026.03.042 |
| 中文关键词: 奥司他韦 药品不良反应 合理用药 病例分析 儿童 |
| 英文关键词: Oseltamivir Adverse drug reaction Rational drug use Case analysis Children |
| 基金项目: |
|
| 摘要点击次数: 423 |
| 全文下载次数: 503 |
| 中文摘要: |
| 目的探究儿童在使用磷酸奥司他韦过程中出现的药品不良反应( ADR)的特点及发生规律。方法采用回顾性分析方法，对 2022年 1月至 2024年 12月南通大学附属常州儿童医院向国家药品不良反应监测中心提交的 52例与磷酸奥司他韦相关的 ADR报告进行统计分析。结果 52例 ADR报告中，男女比例为 1.17∶1，>1~6岁年龄段病儿 ADR占比最高( 39例，75.00%)；曾有药物过敏史者为 5例( 9.62%)；病儿临床诊断以上呼吸道感染最多( 21例， 40.38%)，经过病原学检验的有 38例(73.08%)； ADR主要发生在用药后 3d内( 45例， 86.54%)，累及器官 /系统损害共计 69例次，主要表现为消化系统损害和神经 -精神系统损害；另外病例中存在联合用药 41例( 78.85%)； ADR均为一般不良反应，经处理后病儿均好转或痊愈，对原患疾病未造成明显影响。结论对于儿童病人而言，在使用磷酸奥司他韦时应严格按照说明书指导给药，并加大对药物使用的监控力度，以此来尽可能降低 ADR的发生率，保障儿童病人的用药安全。 |
| 英文摘要: |
| Objective To investigate the characteristics and occurrence patterns of adverse drug reactions (ADRs) associated with os.eltamivir phosphate in a children's hospital.Methods We conducted a retrospective analysis of 52 ADR reports related to oseltamivirphosphate submitted to the National Center for Adverse Drug Reaction Monitoring from the Affiliated Changzhou Children's Hospital ofNantong University between January 2022 and December 2024.Results Among the 52 ADR cases, the male-to-female ratio was 1.17: 1. Children aged >1-6 years had the highest proportion of ADRs (39 cases, 75.00%). Five cases (9.62%) had a history of drug allergy.The most common clinical diagnosis was upper respiratory tract infection (21 cases, 40.38%), and etiological testing was performed in38 cases (73.08%). ADRs primarily occurred within 3 days following medication (45 cases, 86.54%), involving a total of 69 instances oforgan/system impairment, with digestive system and neuropsychiatric system impairments being the main manifestations. Concurrentmedication use was recorded in 41 cases (78.85%). All ADRs were mild, and all children improved or recovered after management,with no significant impact on the primary illness.Conclusions For pediatric patients, oseltamivir phosphate should be administeredstrictly according to the prescribing information. Drug use monitoring should also be enhanced to minimize the incidence of ADRs andensure medication safety in children. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
